Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (ADH1)
NZ837050APending Publication Date: 2026-09-25CALCILYTIX THERAPEUTICS INC +1
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- NZ837050
- Authority / Receiving Office
- NZ · NZ
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-03-10
- Filing Date
- 2021-09-16
- Publication Date
- 2026-09-25
Smart Images
Figure 00000105_0000 
Figure 00000105_0001 
Figure 00000106_0000
Abstract
The present disclosure provides a method of treating an autosomal dominant hypocalcemia type 1 (ADH1) with a therapeutically effective amount of a compound of formula (I), in particular CLTX-305, wherein the therapeutically effective amount of the compound increases a blood calcium concentration (cCa) to a range of about 7.5 mg / dL to about 10.5 mg / dL, such as about 8.5 mg / dL to about 10.5 mg / dL. Also provided herein is a dosing finding method for treating an autosomal dominant hypocalcemia type 1 (ADH1) with a therapeutically effective amount of a compound of formula (I) or CLTX-305 according to one or more dosing regimens.
Need to check novelty before this filing date? Find Prior Art